Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) finished Thursday with a subtraction of -$0.2 to close at $0.20, a downside of -48.90 percent. An average of 2,801,460 shares of common stock have been traded in the last five days. There was a fall of -$0.7656 in the past week, and it reached a new high 2 times over the past 12 months. The last 20 days have seen an average of 1,035,255 shares traded, while the 50-day average volume stands at 546,134.
BCLI stock has decreased by -88.29% in the last month. The company shares reached their 1-month lowest point of $0.1693 on 09/28/23. With the stock rallying to its 52-week high on 03/31/23, shares of the company touched a low of $0.39 and a high of $4.56 in 52 weeks. It has reached a new high 13 times so far this year and lost -87.51% or -$1.4351 in price. In spite of this, the price is down -95.51% from the 52-week high.
Financial Health
The quick ratio of Brainstorm Cell Therapeutics Inc. for the three months ended June 29 was 0.16, and the current ratio was 0.16, indicating that the company is not able to meet its debt obligations.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Brainstorm Cell Therapeutics Inc.’s return on assets was -180.22%.
Earnings Surprise
The company posted a net income of -$5.33 million in the quarter, while revenues were shrunk -32.08%. The analyst consensus anticipated Brainstorm Cell Therapeutics Inc.’s latest quarter earnings to come in at -$0.15 per share, but it turned out to be -$0.27, a -80.00% surprise. Shareholders own equity worth $45.02 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Brainstorm Cell Therapeutics Inc. (BCLI) price momentum. RSI 9-day as of the close on 28 September was 6.05%, suggesting the stock is oversold, with historical volatility in this time frame at 370.67%.
As of today, BCLI’s price is $0.5561 -78.89% or -$0.7656 from its 5-day moving average. BCLI is currently trading -88.29% lower than its 20-day SMA and -93.60% lower than its 100-day SMA. However, the stock’s current price level is -89.16% below the SMA50 and -85.87% below the SMA200.
The stochastic %K and %D were 3.00% and 2.93%, respectively, and the average true range (ATR) was 0.1648. With the 14-day stochastic at 2.66% and the average true range at 0.1576, the RSI (14) stands at 10.42%. The stock has reached -0.4062 on the 9-day MACD Oscillator while the 14-day reading was at -0.5985.
Analyst Ratings
Maxim Group upgraded Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) to a a Buy rating in its most recent analyst report. Previously, the stock was rated as a Hold. The consensus rating for Brainstorm Cell Therapeutics Inc. (BCLI) among analysts is Hold. According to current brokerage recommendations, 0 brokerage firms advise that investors sell BCLI, while 1 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 0 others rate it as a “buy”.
What is BCLI’s price target for the next 12 months?
Analysts predict a range of price targets between $10.00 and $10.00, with a median target of $10.00. Taking a look at these predictions, the average price target given by analysts for Brainstorm Cell Therapeutics Inc. (BCLI) stock is $10.00.
